[go: up one dir, main page]

AU2001278003A1 - Bacteriophage having multiple host range - Google Patents

Bacteriophage having multiple host range

Info

Publication number
AU2001278003A1
AU2001278003A1 AU2001278003A AU7800301A AU2001278003A1 AU 2001278003 A1 AU2001278003 A1 AU 2001278003A1 AU 2001278003 A AU2001278003 A AU 2001278003A AU 7800301 A AU7800301 A AU 7800301A AU 2001278003 A1 AU2001278003 A1 AU 2001278003A1
Authority
AU
Australia
Prior art keywords
bacteriophage
host range
multiple host
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278003A
Inventor
Sankar Adhya
Carl R. Merril
Deal Scholl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2001278003A1 publication Critical patent/AU2001278003A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14211—Microviridae
    • C12N2795/14232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Toys (AREA)
  • Feedback Control In General (AREA)

Abstract

The present invention discloses compositions and methods for the prophylaxis and treatment of bacterial infections by the use of polyvalent bacteriophage having multiple host range.
AU2001278003A 2000-07-25 2001-07-25 Bacteriophage having multiple host range Abandoned AU2001278003A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22098700P 2000-07-25 2000-07-25
US60/220,987 2000-07-25
PCT/US2001/023390 WO2002007742A2 (en) 2000-07-25 2001-07-25 Bacteriophage having multiple host range

Publications (1)

Publication Number Publication Date
AU2001278003A1 true AU2001278003A1 (en) 2002-02-05

Family

ID=22825862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278003A Abandoned AU2001278003A1 (en) 2000-07-25 2001-07-25 Bacteriophage having multiple host range

Country Status (8)

Country Link
US (1) US7163818B2 (en)
EP (1) EP1305038B1 (en)
AT (1) ATE305793T1 (en)
AU (1) AU2001278003A1 (en)
CA (1) CA2417188A1 (en)
DE (1) DE60113851T2 (en)
ES (1) ES2252263T3 (en)
WO (1) WO2002007742A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895534A1 (en) * 1996-04-15 1999-02-10 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
DE60231168D1 (en) 2001-06-15 2009-04-02 Prysmian Cables & Systems Ltd Connecting optical fibers
ES2283581T3 (en) * 2001-07-18 2007-11-01 Instytut Immunologii I Terapii Doswiadczalnej-Pan PROCEDURES FOR THE PREPARATION OF POLIVAL BACTERIOPHAGES FOR THE TREATMENT OF BASCTERIAL INFECTIONS.
GB0209680D0 (en) 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
US7588929B2 (en) 2002-12-09 2009-09-15 Phage Biopharm Llc Production of bacteriophage compositions for use in phage therapy
GB0300597D0 (en) 2003-01-10 2003-02-12 Microbiological Res Authority Phage biofilms
US7951579B2 (en) 2003-04-07 2011-05-31 Board of Trutees of the University of Arkansas Method for bacteriophage delivery and amplification
AU2004258731B2 (en) * 2003-07-23 2010-02-25 Biocontrol Limited Bacteriophage-containing therapeutic agents
GB0320838D0 (en) 2003-09-05 2003-10-08 Univ Nottingham Disinfection of foodstuffs
US20090191254A1 (en) * 2004-12-06 2009-07-30 The Govt. Of The U.S.A., Centers For Disease Control And Prevention Inhibition of biofilm formation using bacteriophage
WO2006066224A2 (en) * 2004-12-14 2006-06-22 Yale University Virulence targeted antibiotics
CA2495138C (en) * 2005-01-20 2012-10-23 Alison Jane Basile Multiplexed analysis for determining a serodiagnosis of viral infection
WO2006095345A2 (en) * 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
EP1907534B2 (en) * 2005-07-12 2024-04-10 Micreos B.V. Bacteriophage and their uses
US20090053179A1 (en) * 2005-10-05 2009-02-26 Internalle, Inc. Method for using liberated dormant bacteriophage and environmental stress to reduce infectious bacteria
WO2007113657A1 (en) 2006-04-04 2007-10-11 Centre National De La Recherche Scientifique - Cnrs Process of production of bacteriophage compositions and methods in phage therapy field
KR100781669B1 (en) * 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 Bacteriophage with Staphylococcus Aureus Specific Killing Capacity
KR100759988B1 (en) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 Antibacterial Protein Specific to Staphylococcus Aureus
FR2910492B1 (en) * 2006-12-20 2013-02-15 Bio Modeling Systems Ou Bmsystems PROCESS FOR THE PREPARATION OF MODIFIED BACTERIOPHAGES BY INSERTION OF RANDOM SEQUENCES IN THE TARGETING PROTEINS OF SAID BACTERIOPHAGES
FR2910493B1 (en) 2006-12-20 2012-12-14 Bio Modeling Systems Ou Bmsystems METHOD FOR THE RANDOM DIVERSIFICATION OF A GENETIC SEQUENCE FOR PRESERVING THE IDENTITY OF CERTAIN INTERNAL SEGMENTS OF THE GENETIC SEQUENCE
GB0704553D0 (en) 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
WO2008121830A2 (en) * 2007-03-30 2008-10-09 National Research Council Of Canada Phage receptor binding proteins for antibacterial therapy and other novel uses
KR100910961B1 (en) * 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 Bacteriophage or lysate protein derived from it effective in treating biofilm of Staphylococcus aureus
US20100092431A1 (en) * 2008-05-15 2010-04-15 Auburn University Edwardsiella Ictaluri Bacteriophage and Uses Thereof
US8377866B2 (en) * 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
WO2012145676A1 (en) * 2011-04-20 2012-10-26 Dcb-Usa Llc Polypeptides and bacteriophages specific to klebsiella pneumoniae capsular type strains
WO2013010660A1 (en) * 2011-07-15 2013-01-24 Medizinische Hochschule Hannover (Mhh) Enzymes having alpha2,9 endosialidase activity
RU2518303C2 (en) * 2012-06-29 2014-06-10 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) ANTIBACTERIAL COMPOSITION, STRAIN OF BACTERIOPHAGE Escherichia coli, USED FOR OBTAINING THEREOF
US9617522B2 (en) 2013-09-05 2017-04-11 Massachusetts Institute Of Technology Tuning bacteriophage host range
EP2893933A1 (en) * 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
GB201417805D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifield bacteriophage
GB201417811D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417810D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417808D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modified bacteriophage
EP3018201A1 (en) 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
JP6842417B2 (en) * 2014-12-16 2021-03-17 シー３ジェイ セラピューティクス インコーポレイテッド Compositions and Methods for In vitro Viral Genome Engineering
EP3440204A1 (en) 2016-04-08 2019-02-13 Phico Therapeutics Ltd Modifying bacteriophage
WO2017174810A1 (en) 2016-04-08 2017-10-12 Phico Therapeutics Ltd Modified bacteriophage
EP3532850A1 (en) 2016-10-28 2019-09-04 Massachusetts Institute Of Technology Synthetic bacteriophages and bacteriophage compositions
KR101822812B1 (en) * 2017-02-22 2018-01-29 주식회사 인트론바이오테크놀로지 Novel Enterococcus faecium bacteriophage Ent-FAP-4 and its use for preventing proliferation of Enterococcus faecium
US10174295B1 (en) * 2017-08-01 2019-01-08 The Charles Stark Draper Laboratory, Inc. Composition of matter: engineering of Escherichia coli phage K1E
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US20220348886A1 (en) * 2018-01-19 2022-11-03 Cytophage Technologies Inc. Genetically Engineered Bacteriophage
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
CN114127270A (en) * 2019-07-18 2022-03-01 慕尼黑科技大学 Host-independent expression of bacteriophages
CN112695017B (en) * 2019-10-23 2022-04-15 吉林大学 Phage vB_Yen_X1 and its application in the prevention and treatment of Yersinia pestis infection
US11584781B2 (en) 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
CN111876400B (en) * 2020-08-06 2022-05-24 昆明理工大学 Normal temperature lyase Sly and polynucleotide for coding same
CN112143747B (en) * 2020-09-09 2022-09-13 昆明理工大学 A kind of bacteriophage lyase and its gene, gene recombinant expression vector and application
CN113215114A (en) * 2021-06-09 2021-08-06 西南石油大学 NDM-1 coliphage and separation method and application thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
PL4392550T3 (en) 2022-06-29 2025-10-06 Snipr Biome Aps. Targeting e coli cells
EP4621049A1 (en) * 2024-03-19 2025-09-24 Invitris GmbH Multispecific particles

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405720A (en) * 1981-03-04 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Silver stains for protein in gels
US4508820A (en) * 1982-08-13 1985-04-02 The United States Of America As Represented By The Department Of Health And Human Services Method for simultaneously monitoring turnover rate in multiple proteins
US4555490A (en) * 1984-06-08 1985-11-26 The United States Of America As Represented By The Department Of Health And Human Services Rapid visualization system for gel electrophoresis
US4703016A (en) * 1986-05-05 1987-10-27 The United States Of America As Represented By The Department Of Health And Human Services Silver stain for rapid, quantitative detection of polypeptides and nucleic acids
US4940659A (en) * 1987-02-20 1990-07-10 Monoclonetics International, Inc. Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome
US4892814A (en) * 1987-06-22 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Method for distinguishing Creutzfeldt-Jakob disease from other dementias
US5817797A (en) * 1988-06-01 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Sequencing DNA; a modification of the polymerase chain reaction
US5292665A (en) * 1989-03-15 1994-03-08 The United States Of America As Represented By The Department Of Health And Human Services Catalyst for preparing polyacrylamide gel which improves the detection of biomaterials by silver staining
AU667462B2 (en) * 1990-11-30 1996-03-28 Monoclonetics International Incorporated Methods for the diagnosis of chronic lower back and cervical pain
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
US5861504A (en) * 1991-05-29 1999-01-19 The United States Of America As Represented By The Department Of Health And Human Services Eleven highly informative microsatelite repeat polymorphic DNA markers
US5378602A (en) * 1991-05-29 1995-01-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Highly informative microsatellite repeat polymorphic DNA markers twenty-[seven]six
US5468610A (en) * 1991-05-29 1995-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Three highly informative microsatellite repeat polymorphic DNA markers
US5429947A (en) * 1992-06-17 1995-07-04 Merril; Carl R. Diagnosing Alzheimer's disease and schizophrenia
CA2186962A1 (en) * 1994-04-05 1995-10-12 Richard M. Carlton Antibacterial therapy with genotypically modified bacteriophage
US5811093A (en) * 1994-04-05 1998-09-22 Exponential Biotherapies, Inc. Bacteriophage genotypically modified to delay inactivations by the host defense system
US20010043924A1 (en) * 1994-04-05 2001-11-22 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
SE506771C2 (en) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusion protein, bacteriophage expressing the protein, their use and hybridoma cells and monoclonals produced by the cells
WO1998005344A1 (en) * 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
CA2474159A1 (en) * 2002-01-23 2003-05-21 Carl R. Merril Method for determining sensitivity to a bacteriophage
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy

Also Published As

Publication number Publication date
DE60113851D1 (en) 2006-02-16
WO2002007742A9 (en) 2002-04-18
US7163818B2 (en) 2007-01-16
WO2002007742A3 (en) 2002-08-08
WO2002007742A2 (en) 2002-01-31
US20030216338A1 (en) 2003-11-20
EP1305038B1 (en) 2005-10-05
WO2002007742A8 (en) 2003-10-30
ES2252263T3 (en) 2006-05-16
ATE305793T1 (en) 2005-10-15
CA2417188A1 (en) 2002-01-31
DE60113851T2 (en) 2006-07-20
EP1305038A2 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
AU2001278003A1 (en) Bacteriophage having multiple host range
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
AU2003291227A1 (en) Antibacterial agents
WO2003088897A3 (en) Fab i inhibitors
SE0102315D0 (en) Compounds
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
GB0125222D0 (en) Composition for the treatment of microbial infections
EP3738591A3 (en) Novel antibacterial agents
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
EP1560821B8 (en) Antibacterial agents
EA200600280A1 (en) COMPOSITIONS BASED ON DERIVATIVES OF LIPOPEPTID ANTIBIOTICS AND METHODS OF THEIR APPLICATION
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
AU2003245928A1 (en) Antibacterial amide macrocycles
AU2002232558A1 (en) Compounds, compositions and methods for treatment of parasitic infections
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
AU2003294565A1 (en) Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
BR0307085A (en) Combination therapy for the treatment of bacterial infections
WO2004034961A3 (en) Antimicrobial agents and uses thereof
NZ509051A (en) Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections
AU2003259159A1 (en) N-aryl-2-oxazolidinones and their derivatives
WO2002057281A3 (en) Aminoglycosides as antibiotics
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2002303480A1 (en) Glycopeptide antibiotics